surviBALL: exploring lncRNA expression at diagnosis for 5-year EFS risk stratification in pediatric B-ALL—a proof of concept
These findings suggest that surviBALL has the potential to complement current risk stratification approaches, particularly by identifying patients at high risk of relapse at diagnosis. As a hypothesis-generating proof of concept, this study highlights the promise of more personalized treatment strategies and warrants further validation in independent cohorts.
Authors
- Chantal Richer
- Manuel Ramı́rez (ORCID: https://orcid.org/0000-0003-0332-6973)
- Javier Arzuaga‐Méndez (ORCID: https://orcid.org/0000-0002-4870-9321)
- Elixabet López-López (ORCID: https://orcid.org/0000-0002-5309-3031)
- Unai Illarregi (ORCID: https://orcid.org/0000-0001-7418-5616)
- Itziar Astigarraga (ORCID: https://orcid.org/0000-0002-5012-0137)
- Daniel Sinnett (ORCID: https://orcid.org/0000-0003-3625-6676)
- Mireia Camós (ORCID: https://orcid.org/0000-0003-3658-7942)
- Nerea Bilbao‐Aldaiturriaga (ORCID: https://orcid.org/0000-0001-6792-7984)
- Idoia Martín‐Guerrero (ORCID: https://orcid.org/0000-0002-0098-1908)
- Ángela Gutiérrez-Camino (ORCID: https://orcid.org/0000-0002-8679-6868)
- Iván Martínez de Estíbariz (ORCID: https://orcid.org/0009-0005-9553-229X)
Institutions
- University of the Basque Country (ES)
- Centre Hospitalier Universitaire Sainte-Justine (CA)
- BioCruces Health research Institute (ES)
- Hospital Infantil Universitario Niño Jesús (ES)
- Sant Joan de Déu Research Foundation (ES)
- Bioef - Fundación Vasca de Innovación e Investigación Sanitarias (ES)
- Université de Montréal (CA)
Publication Details
- Journal
- Molecular and Cellular Pediatrics
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1186/s40348-025-00210-3
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00